Vyome Holdings Inc. (HIND)
HIND trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1427570/000121390026029500/0001213900-26-029500-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | HIND on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2016 |
| SEC CIK | 0001427570 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $320K |
| Net income | -$10.3M |
| Operating income | -$10.5M |
| Net margin | -3209.7% |
| Operating margin | -3269.4% |
| Revenue growth | +24.4% |
| Cash | $5.0M |
| Total assets | $6.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 33.6× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-12 |
| Cash and burn | $7.0M cash; operating cash flow -$1.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 7,018,528 (2026-11-09); 5,644,494 a year earlier; 13,135,478 three years earlier. 3y figure adjusted for splits (1-for-5800 overall). | Cover page 2026-11-09 |
| Reverse splits, 3 years | 3; latest 1-for-4 on 2025-08-15 | Source 2025-08-15 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Kreit & Chiu CPA LLP, Los Angeles, California, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-08-20 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $58K | -$885K | -$628K | $7.0M | No debt tags | $153K | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $27K | -$686K | -$904K | $7.9M | No debt tags | $130K | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | $32K | -$963K | -$1.4M | $8.8M | No debt tags | $153K | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $37K | -$1.2M | -$1.5M | $5.0M | No debt tags | $320K | 10-K 2026-03-18 |
| Q3 2025 2025-09-30 | $35K | -$8.4M | -$1.7M | $5.7M | No debt tags | $345K | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $50K | -$309K | -$306K | $4.1M | No debt tags | $394K | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | $199K | -$294K | -$204K | $2.5M | No debt tags | $2.3M | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | $61K | -$307K | -$3K | $102K | $811K | $4.1M | 10-K 2026-03-18 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B3 | 2025-11-26 |
| Latest annual report ANNUAL REPORT | 10-K | 2026-03-18 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-11-12 |
| Latest current report CURRENT REPORT | 8-K | 2026-08-28 |
| Latest proxy PROXY STATEMENT | DEF 14A | 2026-03-31 |
Source: SEC EDGAR submissions feed, 694 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | 0.0% |
| 1 month | -19.8% |
| 3 months | -26.9% |
| Year to date | -54.1% |
| 1 year | -68.0% |
| From 52-week high | -72.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| PTN | Palatin Technologies Inc. | $6.13 | -1.69% | $10.9M |
| RADX | Radiopharm Theranostics Limited | $0.7676 | +1.00% | $11.1M |
| BFRI | Biofrontera Inc. | $0.5700 | -18.58% | $10.2M |
| ASBP | Aspire-Lakewood Holdings Inc. | $8.06 | -5.29% | $11.3M |
| CLRB | Cellectar Biosciences Inc. | $1.01 | -11.40% | $10.1M |
| AEON | AEON Biopharma Inc. | $0.1407 | -8.04% | $10.1M |
| DARE | Dare Bioscience Inc. | $0.5842 | -11.13% | $11.5M |
| BIVI | BioVie Inc. | $1.08 | -4.42% | $11.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier